AOD-9604: The Fat Loss Peptide

AOD-9604 represents one of the most logical ideas in peptide science: take the part of growth hormone that burns fat and remove everything else. Growth hormone is one of the most potent fat-metabolizing hormones in the body, but using full-length growth hormone for weight management brings a cascade of side effects including insulin resistance, fluid retention, joint pain, and potential tumor growth stimulation. AOD-9604 was designed to solve this problem by isolating the specific fragment of growth hormone responsible for lipolysis.

With over 6,500 monthly searches, AOD-9604 attracts significant interest from people exploring peptide-based approaches to body composition. This guide covers the science, the research, the regulatory status, and what you need to understand before considering it. We do not provide dosing information. AOD-9604 therapy should only be pursued under physician guidance.

What is AOD-9604?

AOD-9604, which stands for Anti-Obesity Drug 9604, is a synthetic peptide corresponding to a modified fragment of human growth hormone (hGH). The full human growth hormone molecule is a 191-amino-acid protein produced by the pituitary gland. AOD-9604 consists of amino acids 177 through 191 of this molecule, the C-terminal fragment, with the addition of a tyrosine amino acid at the N-terminus. This specific region of growth hormone had been identified through earlier research as the portion responsible for the hormone's lipolytic, or fat-metabolizing, activity.

The compound was originally developed by Professor Frank Ng at Monash University in Melbourne, Australia, in collaboration with the pharmaceutical company Metabolic Pharmaceuticals. The research program was motivated by a straightforward clinical problem: growth hormone clearly reduces body fat, but full-length growth hormone therapy for obesity is impractical due to its side effects and cost. If the fat-burning fragment could be isolated and used independently, it could provide the metabolic benefit without the metabolic harm.

The design logic behind AOD-9604 is rooted in the structure-function relationship of growth hormone. Different regions of the growth hormone molecule are responsible for different biological activities. The growth-promoting effects that stimulate IGF-1 production, the diabetogenic effects that raise blood glucose, and the lipolytic effects that promote fat breakdown are mediated by different parts of the protein. By using only amino acids 177 through 191, AOD-9604 retains the lipolytic signaling while lacking the structural domains needed to stimulate growth, raise IGF-1, or cause insulin resistance.

This selectivity has been confirmed in research. AOD-9604 does not increase IGF-1 levels, does not promote organ or tissue growth, does not cause fluid retention, and does not raise blood glucose in studies to date. It operates through a narrower mechanism than full growth hormone, which is both its advantage and, as later clinical trials would reveal, potentially its limitation.

How AOD-9604 works

AOD-9604's mechanism of action involves the stimulation of lipolysis, the process by which stored triglycerides in fat cells are broken down into free fatty acids and glycerol for use as energy. This is the same lipolytic mechanism through which full-length growth hormone reduces body fat, but AOD-9604 activates it without engaging the other signaling pathways that growth hormone uses.

Fat cell metabolism. AOD-9604 stimulates the beta-3 adrenergic receptor pathway in adipocytes (fat cells), which activates hormone-sensitive lipase, the enzyme responsible for breaking down stored fat. This promotes the release of fatty acids from fat cells into the bloodstream, where they can be used as fuel by muscles, the liver, and other tissues. The compound appears to stimulate both lipolysis (fat breakdown) and inhibit lipogenesis (new fat formation), creating a dual effect on fat metabolism.

No IGF-1 stimulation.Unlike full-length growth hormone, AOD-9604 does not stimulate the liver to produce IGF-1. This is important for two reasons: first, elevated IGF-1 is responsible for many of growth hormone's side effects including joint pain, fluid retention, and potential promotion of cell proliferation. Second, the absence of IGF-1 elevation means that AOD-9604 cannot produce the anabolic, tissue-building effects of growth hormone. It is purely a metabolic compound, not a growth-promoting one.

Glucose neutrality. One of the most significant advantages of AOD-9604 over full growth hormone is its neutral effect on glucose metabolism. Growth hormone is diabetogenic, meaning it raises blood glucose and reduces insulin sensitivity, which can be particularly problematic for overweight and obese individuals who often already have impaired glucose metabolism. AOD-9604 does not share this effect, making it theoretically safer for the population most likely to use it.

Cartilage effects. More recent research has identified an unexpected property of AOD-9604: it appears to stimulate the differentiation and proliferation of chondrocytes, the cells responsible for producing and maintaining cartilage. This has led to interest in AOD-9604 for osteoarthritis and cartilage repair applications, a direction that was not part of the original anti-obesity research program. Studies have shown that AOD-9604 can promote proteoglycan and collagen production in cartilage cells, suggesting a potential role in joint health that is independent of its fat metabolism effects.

Research and evidence

Animal studies

The animal data for AOD-9604 is consistent and encouraging. In obese mouse models, AOD-9604 produced significant reductions in body fat without affecting lean body mass, food intake, or growth rate. Studies demonstrated that the compound stimulated lipolysis in fat tissue, reduced fat accumulation, and did so without the hyperglycemia that accompanies full growth hormone treatment. The fat reduction was observed with both injection and oral administration, which is notable because oral availability expands potential delivery options.

Animal studies also confirmed the safety advantages of the fragment approach. AOD-9604-treated animals did not show the elevated IGF-1 levels, glucose intolerance, or organ hypertrophy associated with growth hormone treatment. The metabolic selectivity that was designed into the compound at the molecular level was confirmed at the whole-organism level.

Human clinical trials

Human clinical data for AOD-9604 tells a more complicated story. Early-phase clinical studies showed promising signals for fat reduction and confirmed the compound's favorable safety profile in humans. Participants did not experience the side effects associated with growth hormone therapy, and some studies showed modest reductions in body fat.

However, the pivotal Phase IIb clinical trial, a large, randomized, placebo-controlled study, did not meet its primary endpoint of statistically significant weight loss compared to placebo. This result was disappointing given the strong animal data and effectively ended Metabolic Pharmaceuticals' pharmaceutical development program for AOD-9604 as an anti-obesity drug.

The failure of the Phase IIb trial does not necessarily mean AOD-9604 is ineffective. Clinical trials can fail for many reasons including suboptimal dosing, patient selection, trial duration, and endpoint selection. The compound may have effects that are real but insufficient in magnitude to meet the high bar of a weight loss drug trial, or it may work better in specific patient populations or as part of combination protocols rather than as a standalone treatment. However, the negative trial result means that the human evidence for AOD-9604 as a weight loss agent is weaker than the animal data suggested it would be.

Cartilage research

The more recent cartilage research has opened a potentially more promising direction for AOD-9604. In vitro studies have demonstrated that AOD-9604 stimulates chondrocyte proliferation and proteoglycan synthesis, which are key processes in cartilage maintenance and repair. Animal studies have shown improvements in cartilage quality and joint function in osteoarthritis models.

This cartilage research is still early-stage, but it represents an interesting evolution for a compound originally designed for an entirely different purpose. The mechanism through which a growth hormone fragment promotes cartilage health is not fully understood but may relate to residual growth factor-like signaling in the C-terminal region of growth hormone that affects connective tissue biology.

Regulatory status

AOD-9604 has a unique regulatory history. The Therapeutic Goods Administration (TGA) in Australia has approved AOD-9604 as a Generally Recognized as Safe (GRAS) ingredient for use in food products. This approval is significant because it reflects a regulatory assessment of safety, but it should be understood correctly: it is an approval for food-grade use, not an approval as a pharmaceutical drug for treating obesity or any other medical condition.

In the United States, AOD-9604 is not FDA-approved for any indication. It is available through some licensed compounding pharmacies with a valid physician prescription. The regulatory classification of AOD-9604 under the current peptide framework is evolving, and patients should verify its availability and legal status through their prescribing physician.

For a comprehensive overview of how the peptide regulatory system works in the United States, including the Category 1 and Category 2 classification system, see our guide: Are Peptides Legal?. For information on how peptide therapies are administered and supervised, see our Peptide Therapy Guide.

Safety profile

One of AOD-9604's clearest strengths is its safety profile. Both animal studies and human clinical trials have consistently demonstrated that AOD-9604 does not produce the adverse effects associated with full growth hormone therapy. No significant increases in blood glucose, no elevated IGF-1, no fluid retention, no joint pain, and no organ hypertrophy have been reported.

The TGA's GRAS classification provides additional regulatory-level confidence in the compound's safety, as this designation requires evidence that the substance does not pose significant health risks at intended use levels. Human clinical trials reported no serious adverse events attributable to AOD-9604 treatment.

As with all peptide therapies, physician supervision is recommended. A qualified physician can evaluate whether AOD-9604 is appropriate for your specific situation, establish baseline assessments, and monitor your response to therapy. For those interested in exploring broader approaches to body composition optimization, our weight loss guide covers the full landscape of evidence-based strategies.

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide consisting of a modified fragment of human growth hormone, specifically amino acids 177 through 191 with an added tyrosine residue. It was designed to isolate the fat-metabolizing properties of growth hormone while eliminating the growth-promoting, diabetogenic, and other side effects associated with full growth hormone therapy. The name stands for Anti-Obesity Drug 9604, reflecting its original development purpose.

Does AOD-9604 work for weight loss?

Animal studies consistently show fat-reducing effects without the side effects of growth hormone. However, a large Phase IIb human clinical trial did not meet its primary endpoint of statistically significant weight loss compared to placebo. The compound may have real but modest effects on fat metabolism, and some practitioners use it off-label as part of broader body composition protocols. The human clinical evidence is weaker than the animal data suggested.

Is AOD-9604 approved anywhere?

The Therapeutic Goods Administration in Australia has approved AOD-9604 as a Generally Recognized as Safe food ingredient. This reflects a safety assessment but is not an approval as a pharmaceutical drug for obesity. It is not FDA-approved in the United States. It is available through some compounding pharmacies with a physician prescription.

Is AOD-9604 safe?

AOD-9604 has demonstrated a favorable safety profile across animal studies and human clinical trials. It does not cause the diabetogenic effects, fluid retention, or IGF-1 elevation associated with full growth hormone therapy. The Australian TGA's GRAS classification supports its safety. No serious adverse events have been reported in clinical studies. Long-term safety data from extended use is limited, and physician supervision is recommended for any peptide therapy.

How is AOD-9604 different from growth hormone?

AOD-9604 is a 16-amino-acid fragment of the 191-amino-acid growth hormone protein, containing only the region responsible for fat metabolism. Full growth hormone has multiple biological activities including growth promotion, glucose elevation, and fluid retention. AOD-9604 retains only the lipolytic activity without increasing IGF-1, promoting tissue growth, causing fluid retention, or raising blood glucose. It is specifically designed to provide the fat-burning benefit without the metabolic side effects.